NephroDI Therapeutics

NephroDI Therapeutics, Inc. is a pharmaceutical company dedicated to the development and commercialization of drugs for the treatment of renal concentration disorders. The company's lead program is NDI-5001, a novel kidney-targeted small molecule AMPK activator with the potential to become a first-in-class treatment for congenital nephrogenic diabetes insipidus.